Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in MET-N375S Squamous Cell Carcinoma
NCT04533321Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in squamous cell carcinoma (SCC), sponsored by National University Hospital. Primary endpoints: p-HER2 and p-MET status at 3 years, MET-N375S mRNA copy number at 3 years and 4 more. Status: unknown.
02
Drugs
afatinib
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT04533321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04533321.